Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Septerna, Inc. ( (SEPN) ) is now available.
On September 3, 2025, Septerna, Inc. updated its corporate presentation to highlight advancements in its drug discovery programs and collaborations. The company is progressing with its SEP-479 and SEP-631 programs, aiming for clinical trials in 2026, and has secured significant funding to support operations into 2029. These developments position Septerna as a key player in expanding GPCR-targeted therapies, with potential implications for stakeholders in terms of market opportunities and innovative treatment options.
The most recent analyst rating on (SEPN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Septerna, Inc. stock, see the SEPN Stock Forecast page.
Spark’s Take on SEPN Stock
According to Spark, TipRanks’ AI Analyst, SEPN is a Neutral.
Septerna, Inc. shows potential with strong revenue growth and strategic partnerships, but significant operational inefficiencies and financial risks weigh heavily on its overall score. The technical indicators suggest a bearish trend, and the negative valuation metrics further dampen the stock’s attractiveness.
To see Spark’s full report on SEPN stock, click here.
More about Septerna, Inc.
Septerna, Inc. operates in the pharmaceutical industry, focusing on GPCR drug discovery using its proprietary Native Complex Platform™. The company aims to develop oral small molecules for various diseases, including hypoparathyroidism and mast cell-driven diseases, and has collaborations for metabolic disease treatments.
Average Trading Volume: 333,548
Technical Sentiment Signal: Hold
Current Market Cap: $539.5M
See more insights into SEPN stock on TipRanks’ Stock Analysis page.